ArticleKidney international reports2024
Correlation of Urinary Soluble CD163 Levels With Disease Activity and Treatment Response in IgA Nephropathy.
Article in Kidney international reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Correlation between urinary soluble CD163 and endocapillary proliferation and fibrinoid necrosis in IgA vasculitis with nephritis.Pediatric nephrology (Berlin, Germany) · 2026Article
- A nine-gene diagnostic model for IgA nephropathy based on multi-cohort machine learning: integrating gene expression and immunohistochemical validation.Renal failure · 2026Article
- Management of IgA nephropathy and the expanding role of immunomodulation.Kidney international supplements · 2026Review
- The expanding role of biomarkers in the management of IgA nephropathy.Kidney international supplements · 2026Review
- Association of Urinary Soluble CD163 With Response to Immunosuppressive Therapy and Renal Relapse in IgAN.Kidney international reports · 2026Article
- Urinary Soluble CD163: A Dynamic Biomarker for Monitoring Treatment Response and Relapse in IgA Nephropathy.Kidney international reports · 2026Article
- Exploratory Analysis of Early Renal Function Changes After Transcatheter Aortic Valve Implantation (TAVI): Limited Predictive Value Beyond Baseline Renal Function.Journal of clinical medicine · 2026Article
- Global research trends and hotspots in targeted therapy for IgA nephropathy: a bibliometric and visualization analysis (1999-2025).Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Procedural and Device Neutrality of Post-TAVI Renal Outcomes: A Multivariable Analysis of Valve Type, Size, and Anatomy.Journal of clinical medicine · 2026Article
- Endothelial cell-released CD93 contributes to podocyte injury in idiopathic nephrotic syndrome.Science translational medicine · 2026Article
- New Insights on IgA Nephropathy from the Perspective of Active Lesions and Systemic Inflammatory Responses.ImmunoTargets and therapy · 2026Review
- Biomarkers predicting good prognosis among patients receiving immunosuppressive treatment in IgA nephropathy: the promising role of serum TGF-β1 and MCP-1.Frontiers in immunology · 2026Article
- Kidney biopsy in the diagnosis of immunoglobulin A nephropathy.Frontiers in medicine · 2026Article
- Serum steroid metabolome pattern is associated with the response to prednisolone therapy of male patients with IgA nephropathy.Renal failure · 2025Article
- Defining Disease Modification in IgA Nephropathy: Toward a Paradigm Shift in Management.Kidney international reports · 2025Review
- Role of Systemic Glucocorticoids in Reducing IgA and Galactose-Deficient IgA1 Levels in IgA Nephropathy.Clinical journal of the American Society of Nephrology : CJASN · 2025Article
- Review
- Clinical Predictors of Underlying Histologic Activity in Patients with Lupus Nephritis: A Focus on Urinary Soluble CD163.Journal of clinical medicine · 2025Article
- Expected and verified benefits from old and new corticosteroid treatments in IgA nephropathy: from trials in adults to new IPNA-KDIGO guidelines.Pediatric nephrology (Berlin, Germany) · 2025Review
- TREM2Experimental physiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The TESTING trial demonstrated that corticosteroids reduce the risk of kidney failure in patients with IgA nephropathy (IgAN) but increase the risk of serious adverse events. Reliable noninvasive biomarkers are needed to identify patients who would benefit most from corticosteroid therapy. Previous studies suggest glomerular macrophage infiltration is associated with response to immunosuppressive therapy in IgAN and urinary soluble CD163 ([u-sCD163], a marker of alternatively activated macrophages [M2]c macrophage) is correlated with clinical remission in vasculitis. This study aims to investigate the association between u-sCD163 and response of steroids therapy in IgAN. Methods: We measured u-sCD163 in patients from a large IgAN cohort and Chinese participants of the TESTING trial. The correlation of baseline or serial u-sCD163 and their response of corticosteroids therapy or kidney outcomes were investigated. Results: In cross-sectional analysis, u-sCD163 levels correlated with kidney macrophage infiltration, especially in crescentic areas, and with active lesions. Subgroup analysis of the TESTING cohort showed higher levels u-sCD163 were associated with greater benefits from corticosteroids therapy in proteinuria remission (odds ratio, 35.56 [95% confidence interval, CI: 7.62-292.34] vs. 3.94 [95% CI: 1.39-12.93], Conclusion: u-sCD163 is a reliable noninvasive biomarker associated with active pathological lesions in IgAN and can guide glucocorticoid therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.